- Home
- ATEC vs DNLI Comparison
ATEC vs DNLI Comparison
Compare ATEC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATEC | DNLI |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2006 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ATEC | DNLI |
|---|---|---|
| Price | $17.58 | $17.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $22.36 | ★ $31.58 |
| AVG Volume (30 Days) | ★ 3.2M | 1.3M |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $728,020,000.00 | N/A |
| Revenue This Year | $26.81 | N/A |
| Revenue Next Year | $16.69 | $3,973.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 27.11 | N/A |
| 52 Week Low | $8.81 | $10.57 |
| 52 Week High | $23.29 | $24.35 |
Technical Indicators
Market Signals| Indicator | ATEC | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 38.62 | 54.81 |
| Support Level | $15.42 | $17.88 |
| Resistance Level | $23.29 | $17.95 |
| Average True Range (ATR) | 1.10 | 0.85 |
| MACD | -0.53 | 0.20 |
| Stochastic Oscillator | 27.57 | 68.85 |
Price Performance
Historical ComparisonAbout ATEC Alphatec Holdings Inc.
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.